ArticleScientific reports2025
MTHFR and ABCB1 polymorphisms associated with toxicity in hematological malignancies patients receiving high dose methotrexate.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
High-dose methotrexate(HD-MTX) has been used in clinical treatment of hematological malignancies and toxicity appeared at the same time. Gene polymorphisms may participate in the activity of MTX-related enzymes and induce drug-related toxicity. The influence of MTHFR C677T, MTHFR A1298C and ABCB1 C3435T polymorphisms on the MTX-related toxicity and delay elimination in adult with hematological malignancies is controversial. Here, a total of 111 patients were analyzed. MTHFR C677T, MTHFR A1298C and ABCB1 C3435T gene polymorphisms are related to MTX-related toxicity in adults with hematological malignancies. Age(≥ 60 years) and MTHFR 1298AC were identified as independent risk factors for delayed elimination of MTX. This reminds us that the MTHFR C677T, MTHFR A1298C and ABCB1 C3435T gene polymorphisms are expected to be a useful tool in reducing toxicity and improving outcome in personalized HD-MTX therapy for patients with hematological malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.